Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XYRISE: Xywav in Narcolepsy or Idiopathic Hypersomnia
NCT07625280Phase 3Recruiting
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Jul 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
A Phase 3 trial of sodium oxybate + calcium oxybate + potassium oxybate + magnesium oxybate in narcolepsy, idiopathic hypersomnia (IH), sponsored by Jazz Pharmaceuticals plc. Started Jul 2026; status: recruiting.
02
Drugs
sodium oxybate + calcium oxybate + potassium oxybate + magnesium oxybate
03
Conditions
narcolepsyidiopathic hypersomnia (IH)
Beyond the preview
Go deeper on NCT07625280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07625280.